Key result
Updated 2005 ESC guidelines revise recommendations on five pharmacological strategies for chronic heart failure.
Why the study?
Chronic heart failure is associated with high mortality and morbidity, and patients are often misdiagnosed or underprescribed effective medications, necessitating updated evidence-based guidance.
This review summarizes the 2005 ESC guidelines for the pharmacological management of chronic heart failure, highlighting updates from the 2001 guidelines based on new large-scale clinical trial data.
Answers are grounded in this paper and cite their sources.
Guidelines may curb misdiagnosis and underprescribing in CHF; leaves open optimal implementation strategies.
Chronic heart failure (CHF) is associated with a high burden of mortality and morbidity and is the leading principal hospital diagnosis among older adults. As a result of the complexities associated with this condition and the occurrence of asymptomatic disease and comorbidities, heart failure patients are often misdiagnosed or underprescribed effective medications. The European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of CHF, were developed to provide clinicians with practical, evidence-based guidance on the optimal management of patients with this condition. The guidelines have recently been updated to incorporate diagnostic, safety, and efficacy data from large-scale clinical trials that were not available for the development of earlier guidance documents. This article discusses five pharmacological strategies for the management of CHF (angiotensin-converting enzyme-inhibitors, beta-blockers, diuretics, aldosterone antagonists, and angiotensin-II type-1 receptor blockers) in the context of the 2005 ESC CHF guidelines. Data from recent large-scale, randomized, placebo-controlled trials are discussed and the updated guidelines are compared with recommendations from the earlier 2001 guidance document.
No takes yet. Share an insight, caveat, or question.
Aldo Pietro Maggioni (2005) conducted a review in Chronic heart failure (CHF). Pharmacological strategies (ACE-inhibitors, beta-blockers, diuretics, aldosterone antagonists, and ARBs) was evaluated. The 2005 ESC guidelines for chronic heart failure incorporate new data from large-scale trials to update recommendations on five pharmacological strategies compared to the 2001 guidance.
Synapse has enriched 10 related papers. Consider them for comparative context: